Furthermore, clinical-pharmacogenetic model for prediction of time to occurrence of dyskinesia included female sex (HR = 1.07), age at diagnosis (HR = 0.97), tremor-predominant Parkinson's disease (HR = 0.88), beta-blockers (HR = 0.95), alcohol consumption (HR = 0.99), time from diagnosis to initiation of levodopa treatment (HR = 1.15), <i>CAT</i> rs1001179 (HR = 1.27), <i>SOD2</i> rs4880 (HR = 0.95), <i>NOS1</i> rs2293054 (HR = 0.99), <i>COMT</i> rs165815 (HR = 0.92), and <i>SLC22A1</i> rs628031 (HR = 0.80).
Finally, heterozygotes for <i>SLC22A1</i> rs628031 and carriers of at least one <i>SLC22A1</i> rs628031 A allele had lower odds for dyskinesia (OR = 0.48; 95% CI = 0.24-0.98, <i>p</i> = 0.043 and OR = 0.48; 95% CI = 0.25-0.92; <i>p</i> = 0.027, respectively).